These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 36404396)

  • 1. Safety of anti-SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient-reported outcome study.
    Harada D; Tamura T; Ninomiya K; Kubo T; Kuyama S; Tachibana S; Inoue K; Chikamori K; Kudo K; Ochi N; Maeda Y; Kiura K
    Thorac Cancer; 2023 Jan; 14(3):231-236. PubMed ID: 36404396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.
    Tamura T; Ninomiya K; Kubo T; Kuyama S; Tachibana S; Inoue K; Chikamori K; Kudo K; Ochi N; Harada D; Maeda Y; Kiura K
    Thorac Cancer; 2022 Feb; 13(3):453-459. PubMed ID: 34964270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study.
    Nakashima K; Ishida M; Matsui H; Yoshida C; Nagai T; Shiraga M; Nakaoka H; Otsuka Y; Nakagama Y; Kaku N; Nitahara Y; Kido Y; Hirota Y
    Hum Vaccin Immunother; 2022 Nov; 18(6):2140549. PubMed ID: 36369871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment.
    Narita D; Ebina-Shibuya R; Miyauchi E; Tsukita Y; Saito R; Murakami K; Kimura N; Sugiura H
    Respir Investig; 2023 Mar; 61(2):247-253. PubMed ID: 36567161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET).
    Body A; Ahern E; Lal L; Gillett K; Abdulla H; Opat S; O'Brien T; Downie P; Turville S; Munier CML; Smith C; MacIntyre CR; Segelov E
    BMC Infect Dis; 2022 Jan; 22(1):70. PubMed ID: 35057745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.
    Funakoshi Y; Yakushijin K; Ohji G; Hojo W; Sakai H; Takai R; Nose T; Ohata S; Nagatani Y; Koyama T; Kitao A; Nishimura M; Imamura Y; Kiyota N; Harada K; Tanaka Y; Mori Y; Minami H
    J Infect Chemother; 2022 Apr; 28(4):516-520. PubMed ID: 35090826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of Anti-SARS-CoV-2 S1-specificIgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers.
    Izak M; Stoyanov E; Dezuraev K; Shinar E
    Vaccine; 2022 Jan; 40(3):428-431. PubMed ID: 34903375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
    Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
    ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years.
    Toepfner N; von Meißner WCG; Strumann C; Drinka D; Stuppe D; Jorczyk M; Moor J; Püschel J; Liss M; von Poblotzki E; Berner R; Moor MB; Chao CM
    JAMA Netw Open; 2022 Oct; 5(10):e2237140. PubMed ID: 36255723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff.
    Uwamino Y; Kurafuji T; Sato Y; Tomita Y; Shibata A; Tanabe A; Yatabe Y; Noguchi M; Arai T; Ohno A; Yokota H; Yamasawa W; Uno S; Nishimura T; Hasegawa N; Saya H; Wakui M; Murata M;
    Vaccine; 2022 Feb; 40(7):1019-1025. PubMed ID: 35033389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.
    Oosting SF; van der Veldt AAM; GeurtsvanKessel CH; Fehrmann RSN; van Binnendijk RS; Dingemans AC; Smit EF; Hiltermann TJN; den Hartog G; Jalving M; Westphal TT; Bhattacharya A; van der Heiden M; Rimmelzwaan GF; Kvistborg P; Blank CU; Koopmans MPG; Huckriede ALW; van Els CACM; Rots NY; van Baarle D; Haanen JBAG; de Vries EGE
    Lancet Oncol; 2021 Dec; 22(12):1681-1691. PubMed ID: 34767759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment.
    Buttiron Webber T; Provinciali N; Musso M; Ugolini M; Boitano M; Clavarezza M; D'Amico M; Defferrari C; Gozza A; Briata IM; Magnani M; Paciolla F; Menghini N; Marcenaro E; De Palma R; Sacchi N; Innocenti L; Siri G; D'Ecclesiis O; Cevasco I; Gandini S; DeCensi A
    Eur J Cancer; 2021 Dec; 159():105-112. PubMed ID: 34742157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
    Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
    Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases.
    Poparn H; Srichumpuang C; Sosothikul D; Jantarabenjakul W; Lauhasurayotin S; Techavichit P; Chiangthong K; Poovorawan Y
    Asian Pac J Cancer Prev; 2022 Jun; 23(6):2049-2055. PubMed ID: 35763647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.
    Goshen-Lago T; Waldhorn I; Holland R; Szwarcwort-Cohen M; Reiner-Benaim A; Shachor-Meyouhas Y; Hussein K; Fahoum L; Baruch M; Peer A; Reiter Y; Almog R; Halberthal M; Ben-Aharon I
    JAMA Oncol; 2021 Oct; 7(10):1507-1513. PubMed ID: 34236381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents.
    Fenioux C; Teixeira L; Fourati S; Melica G; Lelievre JD; Gallien S; Zalcman G; Pawlotsky JM; Tournigand C
    JAMA Oncol; 2022 Apr; 8(4):612-617. PubMed ID: 34994776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.